Nemes Rush Group LLC Denali Therapeutics Inc. Transaction History
Nemes Rush Group LLC
- $728 Billion
- Q2 2024
A detailed history of Nemes Rush Group LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Nemes Rush Group LLC holds 700 shares of DNLI stock, worth $21,539. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700
Previous 700
-0.0%
Holding current value
$21,539
Previous $14.4 Million
13.16%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
214Shares Held
121MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.8MShares$424 Million0.25% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$405 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$348 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$302 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$219 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $4.13B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...